Immuneering Corporation (IMRX)
IMRXNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$3.71
+0.0450 (+1.23%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $240.27m
- P/E
- –
- EPS, last 4 quarters
- $-1.03
- Dividend yield
- –
- Day range
- –
- 52-week range
- $3.35 to $8.48
- Average volume
- –
- Previous close
- $3.67
Analysts
3 coveringBuy3 buy, 0 hold, 0 sell
Targets a year out average $12.33, +232.3% from here
Earnings
next estimate $-0.4000Next report
Dec 2025
+41.9%
Mar 2026
+30.0%
Jun 2026
-3.9%
Sep 2026
-27.6%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$13.75m | -$15.34m | -$19.00m | -$25.79m |
| Net income | -$11.58m | -$13.46m | -$17.27m | -$24.19m |
News
8 latest- Astellas, Immuneering Enter Pancreatic Cancer Trial Collaboration RTTNews · 3 days ago
- Immuneering Corporation Appoints Grant C. Bogle to Board of Directors on November 9, 2026Fintel · 5 days ago
- Immuneering Corporation Reports Third Quarter 2026 Financial Results and Provides Business UpdatesFintel · Oct 30, 2026
- Immuneering Reaffirms First-Line Pancreatic Cancer Focus Following FDA Nod For Rasonque RTTNews · Aug 27, 2026
- Immuneering (IMRX) Upgraded to Buy: Here's What You Should KnowZacks · Jul 15, 2026
- Immuneering Corp Appoints Andrew Gengos As CFO RTTNews · Jun 15, 2026
- IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock UpZacks · Jun 12, 2026
- Immuneering Presents Promising Phase 2a Data For Atebimetinib In Pancreatic Cancer; Shares Drop 22% RTTNews · Jun 2, 2026
The company
Immuneering is a late-stage clinical oncology company dedicated to keeping cancer patients alive and helping them thrive, with an initial focus on patients with RAS, RAF, and other MAPK-driven cancers. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering's lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company's development pipeline also includes additional combination opportunities and preclinical stage programs.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- immuneering.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.